Rosiglitazone is a long-acting hypoglycemic drug used in the treatment of type 2 diabetes mellitus, which can be taken once a day and its effect can be maintained for 24 hours. Rosiglitazone belongs to the thiazolidinediones class of hypoglycemic drugs, by increasing the sensitivity of target tissues to insulin to play a role in lowering sugar, can be taken alone to lower sugar, but also with other hypoglycemic drugs (such as acarbose, etc.), can be taken orally once a day, can be taken on an empty stomach or at mealtime, and the effect of the drug can be maintained for 24 hours. Adverse effects of rosiglitazone include hypoglycemia, edema, headache, upper respiratory tract infection, and fatigue. It is contraindicated for those who are allergic to the components of the drug, those with liver or kidney insufficiency, pregnant and lactating women, and patients under 18 years of age. It is necessary to take rosiglitazone correctly under the guidance of a doctor and monitor blood sugar regularly to avoid adverse reactions such as hypoglycemia.